Inhibitors acting at different levels on CXCR4 downstream signalling counteract the SC-induced HIF-1α upregulation in CLL cells, also hindering the SC-mediated pro-survival effect. The gene discussed is HIF1A; the disease is B-cell chronic lymphocytic leukemia.